Bristol-Myers Squibb: I See No Catalysts To Break Underperformance
Source: SeekingAlpha
2025-11-21 08:00:50 ET
Introduction
Bristol-Myers Squibb ( BMY ) is a company that was blessed with multiple early mega blockbuster therapies: Eliquis, Opdivo, and Revlimid (via Celgene). Sometimes, mega blockbusters are more of a curse than a blessing. They lead to tremendous financial fortune for biopharmas, but due to current patent laws, this fortune cannot last. Instead, within 10 or so years, most blockbusters must face the rise of generics. If a company is unable to invest in replacements, then what goes up must come down....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb: I See No Catalysts To Break Underperformance
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
0.17% G/L:
$17.85 Last:
1,296,138 Volume:
$17.92 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
